Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis

The study was a multi-center, single-arm, prospective, non-interventional observational study
in postmenopausal women with osteoporosis who had been treated with Prolia® for osteoporosis
in routine clinical practice.

Inclusion Criteria:

- Enrollment within 4 weeks following administration of the first Prolia® (denosumab 60
mg) injection

- Received Prolia® subcutaneously for treatment of osteoporosis consistent with local
(US/Canada) product label

- Subject or subject's legally acceptable representative has provided informed consent.
Exclusion Criteria:

- Participation in ongoing or previous denosumab clinical trials

- Currently enrolled in another investigational device or drug study, or less than 6
months since ending another investigational device or drug study(s), or receiving
other investigational agent(s)

- Contra-indicated for treatment with Prolia® according to the approved applicable local
product label (US/Canada)

- Subject has any kind of disorder that, in the opinion of the investigator, may
compromise the ability of the subject to give written informed consent.